O	0	4	High	High	JJ	B-NP
O	5	14	frequency	frequency	NN	I-NP
O	15	17	of	of	IN	B-PP
O	18	34	hypermethylation	hypermethylation	NN	B-NP
O	35	37	at	at	IN	B-PP
O	38	41	the	the	DT	B-NP
O	42	44	14	14	CD	I-NP
O	44	45	-	-	HYPH	I-NP
O	45	46	3	3	CD	I-NP
O	46	47	-	-	HYPH	I-NP
O	47	48	3	3	CD	I-NP
O	49	54	sigma	sigma	NN	I-NP
O	55	60	locus	locus	NN	I-NP
O	61	66	leads	lead	VBZ	B-VP
O	67	69	to	to	TO	B-PP
O	70	74	gene	gene	NN	B-NP
O	75	84	silencing	silencing	NN	I-NP
O	85	87	in	in	IN	B-PP
B-Cancer	88	94	breast	breast	NN	B-NP
I-Cancer	95	101	cancer	cancer	NN	I-NP
O	101	102	.	.	.	O

O	104	114	Expression	Expression	NN	B-NP
O	115	117	of	of	IN	B-PP
O	118	120	14	14	CD	B-NP
O	120	121	-	-	HYPH	I-NP
O	121	122	3	3	CD	I-NP
O	122	123	-	-	HYPH	I-NP
O	123	124	3	3	CD	I-NP
O	125	130	final	final	JJ	I-NP
O	131	136	sigma	sigma	NN	I-NP
O	137	138	(	(	(	O
O	138	143	final	final	JJ	B-NP
O	144	149	sigma	sigma	NN	I-NP
O	149	150	)	)	)	O
O	151	153	is	be	VBZ	B-VP
O	154	161	induced	induce	VBN	I-VP
O	162	164	in	in	IN	B-PP
O	165	173	response	response	NN	B-NP
O	174	176	to	to	TO	B-PP
O	177	180	DNA	DNA	NN	B-NP
O	181	187	damage	damage	NN	I-NP
O	187	188	,	,	,	O
O	189	192	and	and	CC	O
O	193	199	causes	cause	VBZ	B-VP
B-Cell	200	205	cells	cell	NNS	B-NP
O	206	208	to	to	TO	B-VP
O	209	215	arrest	arrest	VB	I-VP
O	216	218	in	in	IN	B-PP
O	219	220	G	G	NN	B-NP
O	220	221	(	(	(	O
O	221	222	2	2	CD	B-NP
O	222	223	)	)	)	O
O	223	224	.	.	.	O

O	225	227	By	By	IN	B-PP
O	228	232	SAGE	SAGE	NN	B-NP
O	233	234	(	(	(	O
O	234	240	serial	serial	JJ	B-NP
O	241	249	analysis	analysis	NN	I-NP
O	250	252	of	of	IN	B-PP
O	253	257	gene	gene	NN	B-NP
O	258	268	expression	expression	NN	I-NP
O	268	269	)	)	)	O
O	270	278	analysis	analysis	NN	B-NP
O	278	279	,	,	,	O
O	280	282	we	we	PRP	B-NP
O	283	293	identified	identify	VBD	B-VP
O	294	299	final	final	JJ	B-NP
O	300	305	sigma	sigma	NN	I-NP
O	306	308	as	as	IN	B-PP
O	309	310	a	a	DT	B-NP
O	311	315	gene	gene	NN	I-NP
O	316	321	whose	whose	WP$	B-NP
O	322	332	expression	expression	NN	I-NP
O	333	335	is	be	VBZ	B-VP
O	336	337	7	7	CD	B-NP
O	337	338	-	-	HYPH	O
O	338	342	fold	fold	RB	B-ADJP
O	343	348	lower	low	JJR	I-ADJP
O	349	351	in	in	IN	B-PP
B-Cell	352	358	breast	breast	NN	B-NP
I-Cell	359	368	carcinoma	carcinoma	NN	I-NP
I-Cell	369	374	cells	cell	NNS	I-NP
O	375	379	than	than	IN	B-PP
O	380	382	in	in	IN	B-PP
O	383	389	normal	normal	JJ	B-NP
B-Tissue	390	396	breast	breast	NN	I-NP
I-Tissue	397	407	epithelium	epithelium	NN	I-NP
O	407	408	.	.	.	O

O	409	411	We	We	PRP	B-NP
O	412	420	verified	verify	VBD	B-VP
O	421	425	this	this	DT	B-NP
O	426	433	finding	finding	NN	I-NP
O	434	436	by	by	IN	B-PP
O	437	445	Northern	Northern	NN	B-NP
O	446	450	blot	blot	NN	I-NP
O	451	459	analysis	analysis	NN	I-NP
O	459	460	.	.	.	O

O	461	471	Remarkably	Remarkably	RB	B-ADVP
O	471	472	,	,	,	O
O	473	478	final	final	JJ	B-NP
O	479	484	sigma	sigma	NN	I-NP
O	485	489	mRNA	mRNA	NN	I-NP
O	490	493	was	be	VBD	B-VP
O	494	506	undetectable	undetectable	JJ	B-ADJP
O	507	509	in	in	IN	B-PP
O	510	512	45	45	CD	B-NP
O	513	515	of	of	IN	B-PP
O	516	518	48	48	CD	B-NP
B-Cancer	519	526	primary	primary	JJ	I-NP
I-Cancer	527	533	breast	breast	NN	I-NP
I-Cancer	534	544	carcinomas	carcinoma	NNS	I-NP
O	544	545	.	.	.	O

O	546	553	Genetic	Genetic	JJ	B-NP
O	554	565	alterations	alteration	NNS	I-NP
O	566	568	at	at	IN	B-PP
O	569	574	final	final	JJ	B-NP
O	575	580	sigma	sigma	NN	I-NP
O	581	585	such	such	JJ	B-PP
O	586	588	as	as	IN	I-PP
O	589	593	loss	loss	NN	B-NP
O	594	596	of	of	IN	B-PP
O	597	611	heterozygosity	heterozygosity	NN	B-NP
O	612	616	were	be	VBD	B-VP
O	617	621	rare	rare	JJ	B-ADJP
O	622	623	(	(	(	O
O	623	624	1	1	CD	B-NP
O	624	625	/	/	SYM	I-NP
O	625	627	20	20	CD	I-NP
O	628	639	informative	informative	JJ	I-NP
O	640	645	cases	case	NNS	I-NP
O	645	646	)	)	)	O
O	646	647	,	,	,	O
O	648	651	and	and	CC	O
O	652	654	no	no	DT	B-NP
O	655	664	mutations	mutation	NNS	I-NP
O	665	669	were	be	VBD	B-VP
O	670	678	detected	detect	VBN	I-VP
O	679	680	(	(	(	O
O	680	681	0	0	CD	B-NP
O	681	682	/	/	SYM	O
O	682	684	34	34	CD	B-NP
O	684	685	)	)	)	O
O	685	686	.	.	.	O

O	687	689	On	On	IN	B-PP
O	690	693	the	the	DT	B-NP
O	694	699	other	other	JJ	I-NP
O	700	704	hand	hand	NN	I-NP
O	704	705	,	,	,	O
O	706	722	hypermethylation	hypermethylation	NN	B-NP
O	723	725	of	of	IN	B-PP
O	726	729	CpG	CpG	NN	B-NP
O	730	737	islands	island	NNS	I-NP
O	738	740	in	in	IN	B-PP
O	741	744	the	the	DT	B-NP
O	745	750	final	final	JJ	I-NP
O	751	756	sigma	sigma	NN	I-NP
O	757	761	gene	gene	NN	I-NP
O	762	765	was	be	VBD	B-VP
O	766	774	detected	detect	VBN	I-VP
O	775	777	in	in	IN	B-PP
O	778	780	91	91	CD	B-NP
O	780	781	%	%	NN	I-NP
O	782	783	(	(	(	O
O	783	785	75	75	CD	B-NP
O	785	786	/	/	SYM	I-NP
O	786	788	82	82	CD	I-NP
O	788	789	)	)	)	O
O	790	792	of	of	IN	B-PP
B-Cancer	793	799	breast	breast	NN	B-NP
I-Cancer	800	806	tumors	tumor	NNS	I-NP
O	807	810	and	and	CC	O
O	811	814	was	be	VBD	B-VP
O	815	825	associated	associate	VBN	I-VP
O	826	830	with	with	IN	B-PP
O	831	835	lack	lack	NN	B-NP
O	836	838	of	of	IN	B-PP
O	839	843	gene	gene	NN	B-NP
O	844	854	expression	expression	NN	I-NP
O	854	855	.	.	.	O

O	856	872	Hypermethylation	Hypermethylation	NN	B-NP
O	873	875	of	of	IN	B-PP
O	876	881	final	final	JJ	B-NP
O	882	887	sigma	sigma	NN	I-NP
O	888	890	is	be	VBZ	B-VP
O	891	903	functionally	functionally	RB	B-ADJP
O	904	913	important	important	JJ	I-ADJP
O	913	914	,	,	,	O
O	915	922	because	because	IN	B-SBAR
O	923	932	treatment	treatment	NN	B-NP
O	933	935	of	of	IN	B-PP
O	936	941	final	final	JJ	B-NP
O	942	947	sigma	sigma	SYM	I-NP
O	947	948	-	-	HYPH	I-NP
O	948	951	non	non	AFX	I-NP
O	951	952	-	-	HYPH	I-NP
O	952	962	expressing	express	VBG	B-VP
B-Cell	963	969	breast	breast	NN	B-NP
I-Cell	970	976	cancer	cancer	NN	I-NP
I-Cell	977	981	cell	cell	NN	I-NP
I-Cell	982	987	lines	line	NNS	I-NP
O	988	992	with	with	IN	B-PP
O	993	996	the	the	DT	B-NP
O	997	1001	drug	drug	NN	I-NP
O	1002	1003	5	5	CD	I-NP
O	1003	1004	-	-	HYPH	I-NP
O	1004	1007	aza	aza	NN	I-NP
O	1007	1008	-	-	HYPH	I-NP
O	1008	1009	2	2	CD	I-NP
O	1009	1010	'	'	SYM	I-NP
O	1010	1011	-	-	HYPH	I-NP
O	1011	1024	deoxycytidine	deoxycytidine	NN	I-NP
O	1025	1033	resulted	result	VBD	B-VP
O	1034	1036	in	in	IN	B-PP
O	1037	1050	demethylation	demethylation	NN	B-NP
O	1051	1053	of	of	IN	B-PP
O	1054	1057	the	the	DT	B-NP
O	1058	1062	gene	gene	NN	I-NP
O	1063	1066	and	and	CC	I-NP
O	1067	1076	synthesis	synthesis	NN	I-NP
O	1077	1079	of	of	IN	B-PP
O	1080	1085	final	final	JJ	B-NP
O	1086	1091	sigma	sigma	NN	I-NP
O	1092	1096	mRNA	mRNA	NN	I-NP
O	1096	1097	.	.	.	O

B-Cell	1098	1104	Breast	Breast	NN	B-NP
I-Cell	1105	1111	cancer	cancer	NN	I-NP
I-Cell	1112	1117	cells	cell	NNS	I-NP
O	1118	1125	lacking	lack	VBG	B-VP
O	1126	1131	final	final	JJ	B-NP
O	1132	1137	sigma	sigma	NN	I-NP
O	1138	1148	expression	expression	NN	I-NP
O	1149	1155	showed	show	VBD	B-VP
O	1156	1165	increased	increase	VBN	B-NP
O	1166	1172	number	number	NN	I-NP
O	1173	1175	of	of	IN	B-PP
B-Cellular_component	1176	1187	chromosomal	chromosomal	JJ	B-NP
O	1188	1194	breaks	break	NNS	I-NP
O	1195	1198	and	and	CC	I-NP
O	1199	1203	gaps	gap	NNS	I-NP
O	1204	1208	when	when	WRB	B-ADVP
O	1209	1216	exposed	expose	VBN	B-VP
O	1217	1219	to	to	TO	B-PP
O	1220	1225	gamma	gamma	SYM	B-NP
O	1225	1226	-	-	HYPH	B-NP
O	1226	1237	irradiation	irradiation	NN	I-NP
O	1237	1238	.	.	.	O

O	1239	1248	Therefore	Therefore	RB	B-ADVP
O	1248	1249	,	,	,	O
O	1250	1252	it	it	PRP	B-NP
O	1253	1255	is	be	VBZ	B-VP
O	1256	1264	possible	possible	JJ	B-ADJP
O	1265	1269	that	that	IN	B-SBAR
O	1270	1274	loss	loss	NN	B-NP
O	1275	1277	of	of	IN	B-PP
O	1278	1283	final	final	JJ	B-NP
O	1284	1289	sigma	sigma	NN	I-NP
O	1290	1300	expression	expression	NN	I-NP
O	1301	1312	contributes	contribute	VBZ	B-VP
O	1313	1315	to	to	TO	B-PP
O	1316	1325	malignant	malignant	JJ	B-NP
O	1326	1340	transformation	transformation	NN	I-NP
O	1341	1343	by	by	IN	B-PP
O	1344	1353	impairing	impair	VBG	B-VP
O	1354	1357	the	the	DT	B-NP
O	1358	1359	G	G	NN	I-NP
O	1359	1360	(	(	(	O
O	1360	1361	2	2	CD	B-NP
O	1361	1362	)	)	)	O
B-Cell	1363	1367	cell	cell	NN	B-NP
O	1368	1373	cycle	cycle	NN	I-NP
O	1374	1384	checkpoint	checkpoint	NN	I-NP
O	1385	1393	function	function	NN	I-NP
O	1393	1394	,	,	,	O
O	1395	1399	thus	thus	RB	B-ADVP
O	1400	1408	allowing	allow	VBG	B-VP
O	1409	1411	an	an	DT	B-NP
O	1412	1424	accumulation	accumulation	NN	I-NP
O	1425	1427	of	of	IN	B-PP
O	1428	1435	genetic	genetic	JJ	B-NP
O	1436	1443	defects	defect	NNS	I-NP
O	1443	1444	.	.	.	O

O	1445	1461	Hypermethylation	Hypermethylation	NN	B-NP
O	1462	1465	and	and	CC	I-NP
O	1466	1470	loss	loss	NN	I-NP
O	1471	1473	of	of	IN	B-PP
O	1474	1479	final	final	JJ	B-NP
O	1480	1485	sigma	sigma	NN	I-NP
O	1486	1496	expression	expression	NN	I-NP
O	1497	1500	are	be	VBP	B-VP
O	1501	1504	the	the	DT	B-NP
O	1505	1509	most	most	RBS	I-NP
O	1510	1520	consistent	consistent	JJ	I-NP
O	1521	1530	molecular	molecular	JJ	I-NP
O	1531	1542	alterations	alteration	NNS	I-NP
O	1543	1545	in	in	IN	B-PP
B-Cancer	1546	1552	breast	breast	NN	B-NP
I-Cancer	1553	1559	cancer	cancer	NN	I-NP
O	1560	1570	identified	identify	VBD	B-VP
O	1571	1573	so	so	RB	B-ADVP
O	1574	1577	far	far	RB	I-ADVP
O	1577	1578	.	.	.	O

